ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Preclinical studies of BP-1001 in a murine xenograft model of BCR::ABL1-positive CML cells demonstrated that treated mice had a 2-fold increase in overall survival compared to mice receiving a control liposome [63].